What is Sareum Holdings plc's (SAR.L) StockRank?

MoatMap's StockRank for Sareum Holdings plc (SAR.L) is 14/100, with a Strong Sell signal. This is a composite score combining Quality (20), Value (22), and Momentum (59) factor ranks across MoatMap's 20,000+ stock universe.

Does Sareum Holdings plc have an economic moat?

Sareum Holdings plc (SAR.L) has a Quality factor score of 20/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Sareum Holdings plc a buy, hold, or sell?

MoatMap's current signal for Sareum Holdings plc (SAR.L) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Sareum Holdings plc in?

Sareum Holdings plc (SAR.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SAR.L

STRONG SELLREMOVE

Sareum Holdings plc · Healthcare · United Kingdom · $47M · Avg Vol: $62K/d

StockRank

P/E (TTM)

—

ROE

-178.5%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Early-stage biotech with high cash burn and no commercialized products, failing the Buffett margin of safety lens.

COMPANY DESCRIPTION

Sareum Holdings plc is a clinical-stage biotechnology company focused on developing targeted small-molecule therapeutics for cancer and autoimmune diseases. The company's lead candidate, SDC-1801, targets the TYK2/JAK1 pathways, positioning it in a highly lucrative therapeutic class with significant licensing potential. Operating as a lean, virtual drug developer, Sareum relies on outsourcing research and development to maximize capital efficiency prior to securing pharmaceutical partnerships.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.04	-0.06	-0.06	-0.03	—
Shares	68M	68M	108M	134M	+97.5%
Debt	610,845	1M	876,663	3M	62.5%
Equity	6M	2M	3M	3M	-19.3%
Op CF	-3M	-4M	-5M	-3M	—
Inv CF	-2,685	0	12,083	119,484	—
Fin CF	5M	0	6M	6M	—

PRICE (1M)+7.5%

SMA 50SMA 200

$0.29

RSI (14)

26.7

52W High

$0.39

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-148.5%3.2

ROE

-178.5%4.1

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-22.0%15.1

Piotroski

—28.7

Int. Cover

-2.1x34.7

D/E Ratio

—N/A

Current Ratio

1.58x27.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

26.7x3.7

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

74%63.6

RS 6M

53%94.0

SMA 50/200

1.16x85.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-8900%0.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$47M

P/E (Forward)

-0.1x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SAR.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SAR.L	Sareum Holdings plc(you)	$47M	14	STRONG SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
SBTX.L	SkinBioTherapeutics plc	$34M	21	SELL
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
APTA.L	Aptamer Group PLC	$28M	3	STRONG SELL
4BB.L	4basebio PLC	$110M	5	STRONG SELL
IXI.L	IXICO plc	$25M	29	SELL
POLB.L	Poolbeg Pharma PLC	$56M	39	HOLD
TLSA	Tiziana Life Sciences Ltd	$186M	1	STRONG SELL
BCYC	Bicycle Therapeutics plc	$326M	11	STRONG SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Sareum Holdings plc (SAR.L) — Stock Score Summary

Sareum Holdings plc (SAR.L) has a MoatMap StockRank of 14/100 based on Quality (20/100), Value (22/100), and Momentum (59/100) factor scores. The current signal is STRONG SELL. Early-stage biotech with high cash burn and no commercialized products, failing the Buffett margin of safety lens.

Key Financial Metrics

Price	$0.29
Market Cap	$47M
P/E (Forward)	-0.07
Price/Book	26.67
Return on Equity	-178.5%
Return on Invested Capital	-148.5%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-2M

Sareum Holdings plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Sareum Holdings plc’s (SAR.L) StockRank?: MoatMap’s StockRank for Sareum Holdings plc (SAR.L) is 14/100, with a Strong Sell signal. It is a composite of Quality (20), Value (22), and Momentum (59) factor ranks across MoatMap’s 20,000+ stock universe.
Does Sareum Holdings plc have an economic moat?: Sareum Holdings plc (SAR.L) has a Quality factor score of 20/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sareum Holdings plc a buy, hold, or sell?: MoatMap’s current signal for Sareum Holdings plc (SAR.L) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Sareum Holdings plc in?: Sareum Holdings plc (SAR.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).